AXXESS PHARMA: AXXE Is our new TITAN ALERT!  This one is going to climb fast in our opinion based on revenue and product line.  Next Big News we are waiting to hear is that AXXE will be heading to shelves in the United States!!!!!!

Axxess Pharma: a focused healthcare company dedicated to providing a wde range of products to improve the lives of patients and consumers worldwide.

We believe action defines leadership.

Our 23 wholly-owned prescription and non-prescription products are targeted to improve health-related conditions including several forms of iron deficiency, bone loss, rheumatoid arthritis, migraine headaches, urinary tract infections, infant cradle cap, joint pain and much more. Axxess Pharma intends to market these products with affordable pricing and widespread availability. Our company will continue to tap the well of innovation to develop ever-more effective and affordable treatment options for the patients we serve, and also foster innovation in education, leadership and advocacy.

Personal passion concerning the well-being of chronic illness sufferers is a major driving force and at the heart of our company. Affordable, proven, prescription and non-prescription products are a critical component to our company Business Plan. We balance environmental impact, social contribution, and financial results. Axxess Pharma is publicly traded on the US stock exchange under the ticker symbol: AXXE.

Daniel Bagi, M.D., President is a senior executive physician with 20+ year’s international experience in the medical device/pharmaceutical industry, with an emphasis on Product Development, Business Development and licensing. Expertise in product development as it pertains to clinical development for commercial use; medical affairs and clinical research, specifically oncology and gynecologic topical women’s health products. Good knowledge of international regulatory standards. Secured numerous license deals internationally, between North American pharma companies and local partners. Extensive experience presenting to financial institutions, regulatory agencies, and potential pharmaceutical partners.

Stephen Taylor, Investor/Business Relations: CEO/Pres. of Taylor Capitol, Inc., has provided Investor Relation services for years with a prior background in equity research and investment banking in the Wall Street area. Stephen Taylor possesses a deep network of connections in the investment community. This network ranges from retail brokers, fund managers, wealth managers, Wall Street analysts, investment bankers, private equity firms and senior level management consultants.

NEW Products out and hopefully coming to BIG retail stores in the U.S....Thats the Plan!  Will you get a piece before they do?

This one is going places folks.  We see this one going HIGHER then it is now!   We Believe  AXXE  will be the next TITAN POWER HOUSE PLAY.

Product Launch Date,
Est. Summer 2013

• Trifferex 150
• Soropon
• Gravergol

MORE PRODUCTS TO FOLLOW , Stay tuned TITANS

titanstockalerts has been compensated by a third party, five thousand dollars, for this email advertisement.